Genetic Technologies Limited
GENE · NASDAQ
6/30/2024 | 12/31/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $4,800 | $3,959 | $4,532 | $4,154 |
| % Growth | 21.2% | -12.7% | 9.1% | – |
| Cost of Goods Sold | $2,004 | $5,940 | $5,756 | $5,700 |
| Gross Profit | $2,796 | -$1,981 | -$1,223 | -$1,546 |
| % Margin | 58.3% | -50% | -27% | -37.2% |
| R&D Expenses | $363 | $390 | $723 | $558 |
| G&A Expenses | $548 | $737 | $570 | $791 |
| SG&A Expenses | $5,903 | $3,707 | $3,649 | $4,111 |
| Sales & Mktg Exp. | $1,572 | $1,254 | $1,297 | $1,651 |
| Other Operating Expenses | $0 | -$914 | -$1,013 | -$824 |
| Operating Expenses | $6,266 | $3,182 | $3,359 | $3,845 |
| Operating Income | -$3,470 | -$5,163 | -$4,583 | -$5,391 |
| % Margin | -72.3% | -130.4% | -101.1% | -129.8% |
| Other Income/Exp. Net | -$2,128 | -$1,256 | -$1,718 | -$217 |
| Pre-Tax Income | -$5,598 | -$6,419 | -$6,301 | -$5,608 |
| Tax Expense | $0 | $0 | -$10 | -$148 |
| Net Income | -$5,598 | -$6,419 | -$6,291 | -$5,460 |
| % Margin | -116.6% | -162.2% | -138.8% | -131.4% |
| EPS | -1.13 | -1.59 | -1.95 | -1.69 |
| % Growth | 28.9% | 18.5% | -15.4% | – |
| EPS Diluted | -1.13 | -1.59 | -1.95 | -1.69 |
| Weighted Avg Shares Out | 4,967 | 4,026 | 3,221 | 3,221 |
| Weighted Avg Shares Out Dil | 4,967 | 4,026 | 3,221 | 3,221 |
| Supplemental Information | – | – | – | – |
| Interest Income | $30 | $90 | $140 | $80 |
| Interest Expense | $39 | $13 | $14 | $16 |
| Depreciation & Amortization | $254 | $281 | $346 | $330 |
| EBITDA | -$5,305 | -$4,883 | -$5,941 | -$5,061 |
| % Margin | -110.5% | -123.3% | -131.1% | -121.8% |